Compare AbCellera Biologics Inc (ABCL) vs Estee Lauder Companies Inc (EL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Estee Lauder Companies Inc — how do they compare? AbCellera Biologics Inc trades at $7.26 (market cap $2.35B), while Estee Lauder Companies Inc trades at $80.97 (market cap $30.55B). The key difference: Estee Lauder Companies Inc is far larger — about 13× AbCellera Biologics Inc's market cap, and Estee Lauder Companies Inc pays a 1.66% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | EL | |
|---|---|---|
Market Cap | $2.35B | $30.55B |
Sector | Health | Consumer Staples |
52-Week High | $8.12 | $119.61 |
52-Week Low | $2.78 | $67.23 |
Enterprise Value | $1.99B | $36.72B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Estée Lauder (EL) trades at $84.44, up 0.87% with a bullish technical signal and recent earnings beats. The stock shows strong momentum with three consecutive quarterly EPS beats and a consensus price target of $90.60. However, fundamentals reveal challenges with negative net income of -$1.13B in 2025 and elevated P/E of 147.8, though gross margins remain robust at 74.71%. Recent news highlights strategic investments and product innovation, including the Scent Scanner launch with Jo Malone London.
The outlook is mixed: technical strength and analyst optimism support upside to $90+, but high valuation and profitability concerns pose risks. Investment opportunity lies in execution of growth initiatives and margin recovery, while key risks include competitive pressures and macroeconomic headwinds affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →
